Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV Therapy

ClinicalTrials.gov ID: NCT00000651

Public ClinicalTrials.gov record NCT00000651. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate the safety of zalcitabine (dideoxycytidine; ddC) alone and in combination with zidovudine (AZT) versus AZT alone when administered to asymptomatic patients with a CD4 count = or \< 200 cells/mm3 and symptomatic patients with a CD4 count = or \< 300 cells/mm3. To compare the effectiveness of ddC alone and in combination with AZT versus AZT alone. ddC has been shown to demonstrate an antiviral effect. AZT has been shown to significantly decrease mortality and reduce the frequency of opportunistic infections in patients with AIDS or advanced ARC. After 1 year of AZT therapy, the effectiveness tends to diminish and patients progress with more opportunistic infections and higher mortality rates. Because of the demonstrated antiviral activity, absence of hematologic toxicity, and lack of cross tolerance in laboratory studies of ddC, a study to investigate the long-term effectiveness of ddC in patients with HIV infection who have received AZT therapy is warranted.

Study identification

NCT ID
NCT00000651
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
750 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
13 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Apr 30, 1993
Last update posted
Nov 1, 2021

Ends 1993

United States locations

U.S. sites
40
U.S. states
16
U.S. cities
26
Facility City State ZIP Site status
USC CRS Los Angeles California 90033
UCLA CARE Center CRS Los Angeles California 90095
UCSD Maternal, Child, and Adolescent HIV CRS San Diego California 92103
Ucsd, Avrc Crs San Diego California
Ucsf Aids Crs San Francisco California
Harbor-UCLA Med. Ctr. CRS Torrance California 90502
University of Colorado Hospital CRS Aurora Colorado
Univ. of Miami AIDS CRS Miami Florida 33136
Northwestern University CRS Chicago Illinois
Rush Univ. Med. Ctr. ACTG CRS Chicago Illinois
Indiana Univ. School of Medicine, Infectious Disease Research Clinic Indianapolis Indiana 46202
Tulane Hemophilia Treatment Ctr. New Orleans Louisiana
Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU New Orleans Louisiana
Johns Hopkins Adult AIDS CRS Baltimore Maryland 21287
Massachusetts General Hospital ACTG CRS Boston Massachusetts 02114
HMS - Children's Hosp. Boston, Div. of Infectious Diseases Boston Massachusetts 02115
Bmc Actg Crs Boston Massachusetts 02118
Beth Israel Deaconess - East Campus A0102 CRS Boston Massachusetts 02215
Beth Israel Deaconess Med. Ctr., ACTG CRS Boston Massachusetts 02215
Brigham and Women's Hosp., Div. of Infectious Disease Boston Massachusetts
University of Minnesota, ACTU Minneapolis Minnesota 55455
St. Louis ConnectCare, Infectious Diseases Clinic St Louis Missouri
Washington U CRS St Louis Missouri
NJ Med. School CRS Newark New Jersey 07103
SUNY - Buffalo, Erie County Medical Ctr. Buffalo New York 14215
NYU Med. Ctr., Dept. of Medicine New York New York 10016
Cornell University A2201 New York New York 10021
Memorial Sloan-Kettering Cancer Ctr. New York New York 10021
Beth Israel Med. Ctr. (Mt. Sinai) New York New York 10029
NY Univ. HIV/AIDS CRS New York New York
Univ. of Rochester ACTG CRS Rochester New York
Unc Aids Crs Chapel Hill North Carolina 27599
Carolinas HealthCare System, Carolinas Med. Ctr. Charlotte North Carolina
Duke Univ. Med. Ctr. Adult CRS Durham North Carolina 27710
Regional Center for Infectious Disease, Wendover Medical Center CRS Greensboro North Carolina
Univ. of Cincinnati CRS Cincinnati Ohio 45267
Case CRS Cleveland Ohio 44106
The Ohio State Univ. AIDS CRS Columbus Ohio 43210
Pitt CRS Pittsburgh Pennsylvania 15213
University of Washington AIDS CRS Seattle Washington 98122

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00000651, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 1, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00000651 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →